Renhe Pharmacy Co (SZSE:000650) Research & Development: ¥40 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:000650 Renhe Pharmacy Co Ltd SZSE:000650
83 GF Score
Price ¥5.41
GF Value ¥5.07
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Renhe Pharmacy Co Research & Development?

Renhe Pharmacy Co SZSE:000650 +0.74% 83 Research & Development is ¥40 Mil as of Jun. 2026. GuruFocus rates SZSE:000650 with a GF Score™ of 83/100 and a GF Value™ of ¥5.07 (Fairly Valued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Renhe Pharmacy Co's Research & Development for the three months ended in Jun. 2026 was ¥8 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was ¥40 Mil.

Renhe Pharmacy Co  (SZSE:000650) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Renhe Pharmacy Co Research & Development Related Terms

Renhe Pharmacy Co Research & Development Historical Data

* Premium members only.

The historical data trend for Renhe Pharmacy Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renhe Pharmacy Co Research & Development Chart

Renhe Pharmacy Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.14 50.54 46.37 43.85 45.07

Renhe Pharmacy Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.50 5.77 18.66 7.45 7.78
SZSE:000650
83GF Score
Renhe Pharmacy Co Ltd SZSE:000650
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renhe Pharmacy Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥40 Mil mean?
Renhe Pharmacy Co (SZSE:000650) has a Research & Development of ¥40 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Renhe Pharmacy Co and its competitors.
Is Renhe Pharmacy Co's Research & Development too high?
Renhe Pharmacy Co's current Research & Development is ¥40 Mil. Overall, Renhe Pharmacy Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Renhe Pharmacy Co's Research & Development compare to ZTS?
Renhe Pharmacy Co's Research & Development of ¥40 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Renhe Pharmacy Co and its competitors. Renhe Pharmacy Co's current Research & Development is ¥40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renhe Pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Renhe Pharmacy Co (SZSE:000650) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.07, compared to a current price of ¥5.41 — trading 6.7% above its estimated fair value. The current Research & Development is ¥40 Mil. Renhe Pharmacy Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Renhe Pharmacy Co (SZSE:000650), the current Research & Development is ¥40 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renhe Pharmacy Co (SZSE:000650) Overvalued in 2026?

Based on GuruFocus' analysis, Renhe Pharmacy Co stock appears to be overvalued. The current stock price of ¥5.41 is trading 6.7% above its estimated GF Value™ of ¥5.07. GuruFocus considers Renhe Pharmacy Co to be Fairly Valued.

Key valuation signals for SZSE:000650:

  • Research & Development: ¥40 Mil
  • GF Value™: ¥5.07 vs. price of ¥5.41 (6.7% above fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the SZSE:000650 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renhe Pharmacy Co Business Description

Address No. 998 Honggu Middle Avenue, Greenland Central Plaza, 18th Floor, Yuanchuang International, Zone B, Honggutan New District, Jiangxi Province, Nanchang, CHN, 330038
Renhe Pharmacy Co Ltd is a China-based company engaged in the production and sale of Chinese and Western medicines, raw materials, and health-related products, including oral solid dosage forms, oral liquid dosage forms, large-volume injections, small-volume injections, external washes, liniments, suppositories, ointments, and other dosage forms of pharmaceuticals and health-related products. The company's main products include: Renhe Kelike, Youkadan series, Fuyanjie series, Da Huo Luo capsules, Shanliang eye drops, Qinghuo capsules, and Zhengwei capsules.
83GF Score

Get the complete analysis for SZSE:000650

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.41
Price
¥5.07
GF Value